WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005016922) CARBAZOLE-2-CARBOXAMIDE DERIVATIVES HAVING VANILLOID RECEPTOR ANTAGONIST ACTIVITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/016922    International Application No.:    PCT/EP2004/009082
Publication Date: 24.02.2005 International Filing Date: 12.08.2004
IPC:
C07D 209/88 (2006.01), C07D 417/12 (2006.01), C07D 417/14 (2006.01)
Applicants: GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford Middlesex UB6 0NN (GB) (For All Designated States Except US).
RAMI, Harshad, Kantilal [GB/GB]; (GB) (For US Only).
THOMPSON, Mervyn [GB/GB]; (GB) (For US Only).
WESTAWAY, Susan, Marie [GB/GB]; (GB) (For US Only)
Inventors: RAMI, Harshad, Kantilal; (GB).
THOMPSON, Mervyn; (GB).
WESTAWAY, Susan, Marie; (GB)
Agent: GIDDINGS, Peter, John; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB)
Priority Data:
0319151.7 14.08.2003 GB
Title (EN) CARBAZOLE-2-CARBOXAMIDE DERIVATIVES HAVING VANILLOID RECEPTOR ANTAGONIST ACTIVITY
(FR) DERIVES CARBAZOLE-2-CARBOXAMIDES POSSEDANT UNE ACTIVITE ANTAGONISTE DU RECEPTEUR VANILLOIDE
Abstract: front page image
(EN)A compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4 and R5 are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.
(FR)L'invention concerne un composé de formule (I), un sel ou un solvate de celui-ci, acceptable au plan pharmaceutique, formule dans laquelle R1, R2, R3, R4 et R5 sont tels que définis dans la spécification. L'invention porte également sur un procédé de préparation desdits composés, sur une composition pharmaceutique comprenant lesdits composés et sur l'utilisation desdits composé et de ladite composition en médecine.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)